Media headlines about Chemed (NYSE:CHE) have trended somewhat positive this week, according to Accern. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chemed earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.2461742526108 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Chemed (NYSE CHE) traded up $1.03 during trading hours on Friday, reaching $242.41. 38,603 shares of the company were exchanged, compared to its average volume of 108,061. Chemed has a 12 month low of $155.82 and a 12 month high of $251.00. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48. The stock has a market capitalization of $3,890.00, a PE ratio of 53.99, a price-to-earnings-growth ratio of 5.10 and a beta of 1.16.

Chemed (NYSE:CHE) last posted its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.15. Chemed had a net margin of 4.62% and a return on equity of 27.69%. The company had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. During the same quarter in the prior year, the company posted $1.73 earnings per share. Chemed’s revenue for the quarter was up 6.3% compared to the same quarter last year. equities analysts anticipate that Chemed will post 4.73 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Monday, December 4th. Investors of record on Monday, November 13th were given a dividend of $0.28 per share. The ex-dividend date was Friday, November 10th. This represents a $1.12 dividend on an annualized basis and a yield of 0.46%. Chemed’s payout ratio is 24.94%.

A number of equities analysts have recently issued reports on CHE shares. KeyCorp started coverage on shares of Chemed in a research note on Monday, August 28th. They set a “sector weight” rating on the stock. Royal Bank of Canada reiterated a “hold” rating and set a $209.00 price objective on shares of Chemed in a research note on Friday, September 1st. Zacks Investment Research downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research note on Wednesday, September 6th. Oppenheimer increased their price objective on shares of Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Finally, TheStreet upgraded shares of Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $236.00.

In other Chemed news, VP Michael D. Witzeman sold 1,000 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $250.00, for a total value of $250,000.00. Following the completion of the transaction, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider David Patrick Williams sold 11,000 shares of the firm’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $241.28, for a total transaction of $2,654,080.00. Following the completion of the transaction, the insider now directly owns 74,857 shares of the company’s stock, valued at approximately $18,061,496.96. The disclosure for this sale can be found here. Insiders have sold 46,179 shares of company stock valued at $10,729,699 in the last three months. 4.90% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Chemed (CHE) Stock Price” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/23/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-chemed-che-stock-price.html.

About Chemed

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.